CHRO

Insider Trades

Name	Value	Action	Price	Current Price
Francis Knuettel IICEO, Pres., CFO, Treas & Secty $5.8k6.5k shares BuySep 10, 2024 $0.89 --
Francis Knuettel IICEO, Pres., CFO, Treas & Secty $5.2k5.5k shares BuySep 11, 2024 $0.94 --
Francis Knuettel IICEO, Pres., CFO, Treas & Secty $1.6k1.7k shares BuySep 12, 2024 $0.97 --
Francis Knuettel IICEO, Pres., CFO, Treas & Secty $3.4k3.5k shares BuySep 13, 2024 $0.97 --
Malamut RichardDirector $9.8k10.4k shares BuySep 12, 2024 $0.9447 --

Trade CHRO

About Channel Therapeutics Corporation

Channel Therapeutics Corporation operates as a clinical-stage biotechnology company, committed to the entire process of identifying, advancing, and bringing to market novel therapies aimed at reducing pain. Its research strategy centers on precisely inhibiting the NaV1.7 sodium ion-channel, in addition to other related receptors within the broader NaV family. The firm's flagship investigational drug, CC8464, is currently undergoing Phase 2a clinical evaluation. This compound is being explored for its potential efficacy in treating erythromelalgia and diverse forms of neuropathic pain. Founded in 2002, this New Jersey-based entity maintains its corporate headquarters in Freehold.

CEO: Francis Knuettel II,
IPO Date: Feb 16, 2024

Market Data

Open: $1.25
High: $1.48
Low: $1.23
Volume: 193.1K
Avg Volume: 76.4K
52W High: $54.29
52W Low: $1.23

Valuation

Market Cap: $8.9M
Enterprise Value: $2.9M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-23M
Revenue: $17M
Net Income: $-43M
Cash: $18M
Debt: $34M

Events

EarningsMar 19

actual -1.15204